Literature DB >> 8951199

Diltiazem does not always increase blood cyclosporin concentration.

T E Jones1, R G Morris.   

Abstract

The pharmacokinetic interaction between the calcium channel blocking drug, diltiazem (DTZ), the antifungal agent itraconazole (ICZ) and the immunosuppressive drug cyclosporin (CsA) was studied in a patient with a single lung transplant. The CsA area under curve estimations demonstrated a significant increase when ICZ was co-prescribed (5836 micrograms l-1 h vs 8159 micrograms l-1 h) but no increase when DTZ was co-prescribed with CsA (5836 micrograms l-1 h vs 5069 micrograms l-1 h). Despite widespread use as a CsA-sparing agent, DTZ does not always increase CsA concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951199

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

Review 1.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 2.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

3.  The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Authors:  Sule Kalkan; Mukaddes Gumustekin; Oguz Aygoren; Yesim Tuncok; Ayse Gelal; Hulya Guven
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

4.  Role of cytochrome P450 in drug interactions.

Authors:  Zakia Bibi
Journal:  Nutr Metab (Lond)       Date:  2008-10-18       Impact factor: 4.169

Review 5.  Pharmacokinetic drug-drug interaction and their implication in clinical management.

Authors:  Caterina Palleria; Antonello Di Paolo; Chiara Giofrè; Chiara Caglioti; Giacomo Leuzzi; Antonio Siniscalchi; Giovambattista De Sarro; Luca Gallelli
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.